Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-010: nemtabrutinib + venetoclax versus venetoclax + rituximab in relapsed/refractory CLL/SLL
jRCT2061260028Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Nemtabrutinib + Venetoclax with Venetoclax + Rituximab (2 arms). Primary endpoints: Number of participants experiencing dose-limiting toxicities, Number of participants experiencing adverse events and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
nemtabrutinibvenetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2061260028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260028.